Systematic review of New World cutaneous leishmaniasis: Several points

International Journal of Dermatology

Volumn 48, Issue 2, 2009, Pages 201-

  Khatami, Alireza ^a   Firooz, Alireza ^a   Gorouhi, Farzam ^a   Dowlati, Yahya ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; ANTIPROTOZOAL AGENT;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; GENETIC HETEROGENEITY; HUMAN; LETTER; META ANALYSIS; METHODOLOGY; MUCOSAL DISEASE; RELAPSE; SKIN DEFECT; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; TREATMENT DURATION; NOTE;

ANTIPROTOZOAL AGENTS; HUMANS; ITRACONAZOLE; LEISHMANIASIS, CUTANEOUS;

EID: 59149096834     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03971.x     Document Type: Letter

References (4)

1. Tuon FF, Amato VS, Graf ME, et al. Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. Int J Dermatol 2008; 47: 109-124.
2. Firooz A, Khatami A, Dowlati Y. Itraconazole in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 1446-1447.
3. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005; 19: 80-83.
4. Gangneux JP, Dullin M, Sulahian A, et al. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob Agents Chemother 1999; 43: 172-174.